Chi-Med Reports CFDA Acceptance of Fruquintinib NDA Filing

Hutchison China MediTech (Chi-Med) announced the CFDA accepted the company's New Drug Application for its lead drug, the cancer treatment fruquintinib. In its China Phase III trial, fruquintinib increased survival by 41% in patients with advanced colorectal cancer. Chi-Med reported the data at the ASCO meeting in the US two weeks ago (see story).  The company said the acceptance triggers a milestone payment of $4.5 million from Lilly, its partner for the drug in China. More details.... Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY) Share this with colleagues: // //